SEATTLE, Oct. 7, 2013 -- /PRNewswire/ -- Cell Therapeutics, Inc. - TopicsExpress



          

SEATTLE, Oct. 7, 2013 -- /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are
Posted on: Tue, 08 Oct 2013 12:28:16 +0000

Trending Topics



Recently Viewed Topics




© 2015